Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Assets (2016 - 2025)

Historic Assets for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $504.6 million.

  • Spyre Therapeutics' Assets rose 1983.31% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.6 million, marking a year-over-year increase of 1983.31%. This contributed to the annual value of $608.5 million for FY2024, which is 7799.27% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Assets of $504.6 million as of Q3 2025, which was up 1983.31% from $538.8 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Assets ranged from a high of $608.5 million in Q4 2024 and a low of $52.5 million during Q1 2023
  • For the 5-year period, Spyre Therapeutics' Assets averaged around $279.7 million, with its median value being $207.3 million (2023).
  • In the last 5 years, Spyre Therapeutics' Assets tumbled by 4916.69% in 2022 and then skyrocketed by 82959.79% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Assets stood at $109.9 million in 2021, then tumbled by 35.28% to $71.1 million in 2022, then skyrocketed by 380.52% to $341.9 million in 2023, then soared by 77.99% to $608.5 million in 2024, then decreased by 17.07% to $504.6 million in 2025.
  • Its Assets was $504.6 million in Q3 2025, compared to $538.8 million in Q2 2025 and $569.8 million in Q1 2025.